Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.

Jana SoukupovaPetra ZemankovaKlara LhotovaMarketa JanatovaMarianna BoreckaLenka StolarovaFilip LhotaLenka ForetovaEva MachackovaViktor StraneckySpiros TavandzisPetra KleiblovaMichal VockaHana HartmannovaKaterina HodanovaStanislav KmochZdenek Kleibl

Published in: PloS one (2018)

The objective of CZECANCA is a nationwide consolidation of cancer-predisposition genetic testing across various clinical indications with savings in costs, human labor and turnaround time. Moreover, the unified diagnostics will enable the integration and analysis of genotypes with associated phenotypes in a national database improving the clinical interpretation of variants.

Keyphrases

papillary thyroid
squamous cell
endothelial cells
squamous cell carcinoma
lymph node metastasis
quality improvement
drug delivery
copy number
cancer therapy
genome wide